ARK Invest's 2025 performance data has been finalized, offering a comprehensive look back at the stocks Cathie Wood identified as underappreciated going into the previous year. AMD stock is moving. See the chart and price action here. ARK's WinnersRobinhood Markets, Inc. (NASDAQ:HOOD) emerged as the primary driver of growth for Ark's portfolio over the last year. ending 2025 with a 204% gain. The firm noted that Robinhood successfully transitioned from a meme-stock trading app into a full-service financial ...

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is one of the AI stocks that will go to the moon. On February 18, Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) came under pressure after regulatory filings indicated that Nvidia had divested all its stake in the company. Recursion Pharmaceuticals, Inc. (RXRX) Advances AI Drug Discovery Amid Market Shifts The giant semiconductor company exited its previous holding of 7.71 million shares in Recursion Pharmaceuticals, which is making a name for itself by levera ...

分组1 - Travere Therapeutics reported quarterly earnings of $0.03 per share, aligning with the Zacks Consensus Estimate, compared to a loss of $0.73 per share a year ago, representing an earnings surprise of +16.73% [1] - The company posted revenues of $129.69 million for the quarter ended December 2025, missing the Zacks Consensus Estimate by 8.97%, and this is an increase from year-ago revenues of $74.79 million [2] - Travere has surpassed consensus EPS estimates four times over the last four quarters and topped consensus revenue estimates three times during the same period [2] 分组2 - The stock has underperformed, losing about 27.1% since the beginning of the year, while the S&P 500 has gained 0.5% [3] - The current consensus EPS estimate for the coming quarter is -$0.07 on $135 million in revenues, and for the current fiscal year, it is $0.62 on $673.01 million in revenues [7] - The Zacks Industry Rank for Medical - Biomedical and Genetics is in the top 36% of over 250 Zacks industries, indicating a favorable outlook for the industry [8]

When artificial intelligence (AI) chip maker NVIDIA Corporation (NVDA) heads for the exit, investors instinctively glance at the door. In its latest 13F filing, the chip giant disclosed that it had completely exited its position in the AI-driven drug developer Recursion Pharmaceuticals (RXRX). At the end of Q3 2025, Nvidia held 7.71 million shares. The stake represented a modest slice of its expansive, meticulously managed AI portfolio. Still, the headline carried weight. Traders pushed the stock down as ...

Core Insights - Nvidia has sold its stakes in several AI-focused firms, leading to a decline in their stock prices [1] - The company has added new investments in Intel, Nokia, and Synopsys, while maintaining its holdings in CoreWeave and Nebius Group [1] Nvidia's Stake Sales - Nvidia's divestment included shares in Applied Digital, Recursion Pharmaceuticals, and WeRide, with their stock prices dropping by nearly 10%, 14%, and close to 4% respectively [1] - The regulatory filing did not provide reasons for Nvidia's sales, and the company declined to comment on the changes [1] Impact on Market Confidence - The exit from these stakes may undermine investor confidence in the affected companies, which previously benefited from Nvidia's support [1] - Nvidia's own stock rose about 2%, recovering from earlier losses attributed to concerns over an AI bubble [1] New Investments - Nvidia has increased its positions in Intel, Synopsys, and Nokia, with Synopsys shares rising about 6% and Nokia shares increasing by 2% [1] - The investment in Intel follows Nvidia's announcement of a multibillion-dollar partnership, with ongoing speculation about a potential foundry deal [1] Holdings Maintenance - Nvidia has kept its investments in AI cloud infrastructure providers CoreWeave and Nebius Group unchanged, with both companies' shares climbing close to 5% [1]

周三，Recursion Pharmaceuticals(RXRX.US)盘前股价暴跌，截至发稿，该股跌超13%，报3.46美元。消 息面上，英伟达(NVDA.US)向美国SEC递交的13F文件显示，其在2025年四季度清仓了Recursion Pharmaceuticals。 来源：智通财经网 ...

智通财经APP获悉，周三，Recursion Pharmaceuticals(RXRX.US)盘前股价暴跌，截至发稿，该股跌超 13%，报3.46美元。消息面上，英伟达(NVDA.US)向美国SEC递交的13F文件显示，其在2025年四季度 清仓了Recursion Pharmaceuticals。 ...

Core Insights - The article discusses the integration of AI into a conservative investment strategy, focusing on building a sustainable portfolio system rather than chasing high returns [2][4][38] Investment Strategy Structure - The investment approach utilizes a "barbell" strategy at multiple levels, encompassing a wide range of assets including business interests, private placements, real estate, and investable cash [5] - The investable cash is allocated with 80% in treasuries and high-quality bonds, 15% in dividend aristocrats and quality compounders, and 5% in speculative portfolios [6] Speculative Portfolios - Five speculative themes are identified: space technology, AI in biopharmaceutical discovery, quantum computing, energy/grid resilience, and biomedical companies poised for acquisition [7][17][18][19][20][21] - Each speculative portfolio follows a "mini-ETF" structure, consisting of 10-15 holdings categorized by company size and revenue generation [13] AI Contributions - AI has been instrumental in creating a structured documentation hierarchy for the investment strategy, ensuring clarity and accessibility for future management [9][10][11] - AI assists in developing company filters and screening criteria, ensuring that selected companies meet specific requirements for investment [14][15][16] Performance Modeling - AI helps model the contribution of speculative portfolios to overall returns, aiming for a modest inflation-plus return rather than market-beating performance [24][25][26] - The speculative allocation is designed to provide a potential uplift to the overall portfolio, with a focus on maintaining discipline in position sizing [27][28] Monitoring and Refinement - AI aids in refining portfolio structure by identifying inconsistencies and gaps, as well as tracking relevant metrics for each portfolio [29][30] - Weekly news digests generated by AI keep the investor informed about developments in the speculative holdings, streamlining the research process [31] Intellectual Engagement - The investment strategy allows for continued engagement in fields of interest, providing a structured approach to speculative investing that is intellectually stimulating [34][35][36] - The use of AI enhances the sustainability of this engagement, making it easier to stay informed and organized [37]

Summary of Key Points from the Conference Call on AI-Driven Drug Discovery (AIDD) Industry Overview - **Industry Focus**: Biotechnology, specifically AI-driven drug discovery (AIDD) in the Asia Pacific region [1] - **Current State**: AIDD is transitioning from pilot projects to commercial reality, with significant growth in partnerships and platform deals [2] Core Insights - **Chemistry Models**: These models are mature and have proven to enhance execution efficiency in drug discovery, leading to faster iteration cycles and improved hit-to-lead conversion rates [10][12] - **Biology Models**: While chemistry models are monetizable, biology models, which influence drug development decisions, are still in the validation phase. Their success hinges on demonstrating human relevance through clinical data [3][11] - **2026 as a Pivotal Year**: A series of clinical and translational readouts expected in 2026 will test the validity of biology models, potentially shifting AIDD from execution support to authoritative decision-making [4][16] Investment Opportunities - **CLARITY Framework**: This framework distinguishes between chemistry-execution platforms, which have proven value, and biology-exposed platforms, which may see a revaluation based on upcoming validation results [5][21] - **Recommended Strategy**: The strategy involves pairing investments in established chemistry platforms with selective exposure to emerging biology-validation platforms [6] Key Developments and Case Studies - **Insilico Medicine**: Positive Phase 2a data for its TNIK inhibitor indicates early validation of AI-driven biology models [23][65] - **Recursion Pharmaceuticals**: REC-4881 shows promise in clinical validation, with additional data expected in 2026 [67] - **Absci**: ABS-201, an AI-designed antibody, is in first-in-human studies, with interim data anticipated in 2H26 [66] Market Dynamics - **China's Role**: China is emerging as a key player in AIDD, leveraging its clinical development infrastructure and rapid adoption of AI tools to enhance drug discovery processes [4][72][77] - **Global Trends**: The biopharmaceutical industry is facing pressures such as patent cliffs and declining R&D ROI, driving the need for innovative tools like AIDD [13][41] Risks and Challenges - **Adoption Barriers**: Organizational frictions, such as data silos and misaligned incentives, may hinder the widespread adoption of AIDD technologies [15][50] - **Validation Risks**: Biology models may fail to demonstrate consistent human relevance, which could impact their adoption and valuation [26][70] Conclusion - **Future Outlook**: The next 18-24 months are critical for AIDD, with multiple programs expected to generate early clinical signals that could validate the efficacy of AI in drug discovery [56][70] - **Investment Implications**: As biology models gain validation, there may be a shift in how AIDD companies capture value, moving towards co-development and downstream economic participation [69][71]

Group 1: DraftKings - DraftKings shares lost 8% in value last year and closed 35% below their 2025 peak due to slowing growth and competition from platforms like Kalshi and Polymarket [4] - Concerns about competition disrupting DraftKings' growth are considered overblown, as the brand's recognition and partnerships provide significant marketing advantages [5][6] - DraftKings is diversifying its revenue streams, with casino-style gaming accounting for nearly half of its revenue, which may remind investors of its growth potential [7] Group 2: Recursion Pharmaceuticals - Recursion Pharmaceuticals experienced a 44% pullback last year, but 2026 could be a pivotal year for the company [8] - The company has developed an AI-powered drug discovery platform, Recursion OS, which can analyze 65 petabytes of data to predict drug performance [9]